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Advances in cardiology patient care has lead to a decrease in
hospital mortality rates among patients with acute myocar-
dial infarction (AMI). However, the continued the persis-
tently high worldwide incidence of ischaemic heart disease
supports interest in the pathogenesis and natural history of
myocardial damage (Drapkina et al. 2000; Arzamastsev
et al. 2003; Saprunova et al. 2003; Golikov, 2004) as this
may help in the development of new more effective forms of
treatment.
Presently, treatment for ischaemic heart damage relies on
the simulati on actions of natural antistressor and anti-is-
chaemic mechanisms. The administration of metabolites, or
of their synthetic analogues, that affect different parts of the
pathogenetic chain (Meyerson 1984).
Thus, according to the Guidelines of the Task Force of
the European Society of Cardiology (2000) and subsequent
Russian Guidelines (2001), treatment for developed MI
should rely on the use of beta-blockers, nitrates, calcium
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Summary
This study investigated the effects of the L-17 compound of the group of substituted
5R1, 6H2-1,3,4-thiadiazine-2-amines on the inflammatory cellular infiltration and
myocardial remodelling which occurs after acute myocardial infarction (MI) in rats.
The study is based upon recent clinical and experimental work which demonstrated
the role of local and systemic inflammatory reactions in postinfarction remodelling.
Acute MI in rats was induced by left coronary artery coagulation. Animals were
sacrificed on day one, five and seven after MI induction. The myocardiumal samples
were taken from all parts of the heart and examined by histology. This included
areas of infarction, infraction and areas that were peri-infarctiom and left ventricular
areas distant from the damaged tissues. Serum activity of creatine phosphokinase
(CPK), aspartate aminotransferase (AST), isoenzymes 1 and 2 and lactate dehydroge-
nase (LDH1-2) were investigated on the same three days, before and in the process
of MI development was investigated (at days 1, 5 and 7). The L-17 compound to
not only decreased the area of initial infarction but also changed the pattern of
inflammatory reaction in the affected myocardium fundamentally. Laboratory studies
of effects of L-17 compound on the development and course of experimental MI
showed that administration decreased blood AST and CPK levels significantly and
provided useful the data about the correlation between the activity of these enzymes
and the dimensions of the significantly necrotic area. In this model of experimental
MI the use of the L-17 compound induced led to the replacement of the exudative
destructive inflammation that is seen under standard conditions with a more cellular
‘‘productive’’ pattern of inflammation, with associated reduction in initial necrosis
area and the, decrease in myocardial ischaemia and reperfusion injury may account
for the accelerated repair process.
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channel blockers and antiplatelet agents (aspirin, thienopyri-
dines, platelet glycoprotein IIb ⁄ IIIa receptor antagonists).
However, these medications do not affect either the tissue or
the systemic the tissue inflammatory process associated with
MI, (Smith et al. 1977).
The inflammatory reaction is a component not only of the
ischaemia but also of the reperfusion injury to the myocar-
dium, thus contributing to the spread of the necrotic area
(Tommasi et al. 1999). In addition, the pattern of necrosis
formation can lead to cause abnormal left ventricular remod-
elling in MI (Chukaeva et al. 2007). Moreover, reduction in
scar size is associated with prevention of secondary waves of
myocardial necrosis (Sarkisov, 1979).
A number of recent studies have supported this view. Acti-
vation of cellular effectors of inflammation has an adverse
effect on myocardial function in AMI (Engler et al. 1986;
Kuzuya et al. 1991). The dimensions of the infarction area
correlate with indicators of acute-phase response (Myagkov
et al. 1993). Therefore, lower baseline CRP level are asso-
ciated with a more favourable prognosis for six months after
MI (Hudson et al. 1999). The role of the inflammatory reac-
tion in MI is further confirmed by the fact that removing
neutrophils from blood or adding agents inhibiting leucocyte
infiltration contributed to reducing the dimensions of infarc-
tion area in animal studies (Engler et al. 1986; Dinerman
et al. 1990). Therefore the objective of the present study
was to investigate the effects of L-17 compound of the
group of substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines,
known to have effects on the myocardium, on the inflamma-
tory cellular infiltration and myocardial remodelling after
acute MI in rats.
Materials and methods
L-17 compound of the group of substituted 5R1, 6H2-1,3,4-
thiadiazine-2-amines was used to treat experimental MI in
rats (Figure 1).
This compound was synthesized in the Institute of
Organic Synthesis, Ural Branch of RAS, as part of a series
of several active substances that affect metabolism and
inflammation. The compound is a registered invention (Uni-
ted States Patent No 6313111 of 6 November 2001, PCT
RF Patent No 2259371 of 27 August 2005). Choice of this
compound was because compound L-17 is known to be bio-
logically active and known to have myorelaxing (United
States Patent No 4309426 of 20 November 1980), antispas-
modic and antiaggregatory (Novikova et al. 1992; Logvino-
va et al. 2010) activity but has not yet been investigated in
an in vivo pathogenetic model system. The findings in treat-
ment for experimental MI were also protected by a patent
(PCT RF Patent No 2395850 of 27 July 2010).
Model of acute MI
Modelling of an AMI in rats was performed as described
previously (PCT RF Patent No 2407062 of 20 December
2010). This method is based on operative modelling of MI
in rats, which is characterized by a sequence of the follow-
ing steps: skin is incised and muscles exposed on the left side
of the chest; pectoral muscles are spread to expose costal
arches and intercostal muscles; the intercostal muscles are
dissected at the level of the 4–5 intercostal space for 1 cm;
heart is visualized; and coagulation is performed over a stan-
dard limited area of the branches of the left coronary artery
in its middle or lower third. Coagulation is performed with
an ‘L’-shaped instrument to give a cauterizing surface area
of 2.5 · 3.0 mm, preheated using an alcohol lamp which
allows clear visualization of the heart during coagulation.
The thoracotomy wound is closed with a running suture
using an atraumatic needle; pneumothorax is eliminated
using a needle syringe; and the skin incision is closed. This
method increases the likelihood of a positive result (i.e an
AMI) while minimizing operative time and increasing the
time for the experiment itself. In addition this method nei-
ther disturbs the heart rhythm nor causes arrhythmias asso-
ciated with an electric current effect.
Within 10 min after infarction modelling, animals’
behavioural reactions return fully to the preoperative level.
No deaths were recorded. Assessment of the animals’ behav-
iour at 24 h revealed no signs of abnormal behavioural reac-
tions: the animals were active; and they react to sound and
light stimulation without any delay.
Animal preparation
Twelve-week-old male random-bred male rats were used.
They were housed at 23–25 C in a 12:12-h light–dark cycle
with ad libitum food and water.
Acute MI was induced by left coronary artery coagulation
as described previously. Rats were anesthetized by intraperi-
toneal injection of ketamine (50 mg ⁄kg) and xylazine
(10 mg ⁄kg). They were intubated and ventilated, and the
procedure was performed as outlined above. Coagulation
was performed over the standard limited area of the
branches of the left coronary artery in its middle or lower
third. Controls were sham-operated rats which underwent
the same operation but, without controls were coronary
artery coagulation. The animal experiments were approved
and performed according to the Direction 86 ⁄609 ⁄EEC
(1986) of the EU Council and the European convention on
the Protection of Vertebrates used for Experimental and
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Figure 1 Structural formula of L-17 compound of the group of
substituted 5R1, 6H2-1,3,4-thiadiazine-2-amines.
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Other Scientific Purposes (1990) and the ORDER of USSR
Ministry of Health of August 12, 1977, No 755 ‘On mea-
sures to further improve the organizational form of the use
of experimental animals’.
Experimental protocol
Fifty-two random-bred male rats weighing 180–240 g were
studied. Experiments were conducted as follows: animals
with experimental MI model were divided into two groups,
15 rats in each group. The first group included white rats
that received L-17 compound intraperitoneally at a dosage
of 40 mg ⁄kg every 24 h; the second group received sodium
chloride solution intraperitoneally; the control group of
intact animals without experimental AMI included 10 rats.
Animals were sacrificied for the study on days one, five
and seven after being anesthetized with Aethaminalum-
natrium intraperitoneally at a dosage of 40 mg ⁄kg.
At harvesting of the hearts for subsequent histological
evaluation, gross observations in all test cases showed the
presence of the distinct infarction area in myocardium. No
lung changes and no pleural effusions were noted. Gross
observation did not reveal any visible changes in abdominal
organs (liver, spleen, intestinal loops) or other tissues.
The myocardium from all hearts were examined sampling
both areas of infarction and peri-infarction myocardial
areas, as well as left ventricular areas distant from the dam-
aged tissues. Paraffin blocks were prepared using standard
methods. Serial sections (5–6 micron) of 5–6 micron were
stained with haematoxylin and eosin according to Van Gie-
son and Weigert (Lillie 1977; Bancroft & Stevens 1996).
For biochemical analysis, 3 ml of blood was obtained by a
heart puncture for subsequent centrifugation and serum sepa-
ration. Serum activity of creatine phosphokinase (CPK),
aspartate aminotransferase (AST), isoenzymes 1 and 2 and
lactate dehydrogenase (LDH1-2) before and in the process of
MI development was investigated at the same time intervals.
Laboratory blood tests were performed using the follow-
ing devices and diagnostic systems:
• ‘Immunochemistry Systems’ biochemical analyzer by
Beckman Coulter, Inc. (Brea, CA, USA)
• Diagnostic Systems by DSL, Inc. (Webster, TX, USA)
• ‘Multiscan’ Spectrophotometer by Labsystems Ltd. (Hel-
sinki, Finland)
• ‘Glycomat DS5’ Automatic Analyzer by Drew Scientific
Ltd. (Dallas, TX, USA)
Tolerability of L-17 compound
Tolerability of L-17 compound in animals was estimated as
quite satisfactory: there were no detected cases of pain reac-
tions or necrobiotic changes at injection sites, no postopera-
tive wound infections and no pleural empyemas, except for
slowing down of animals’ reactions to sound and light stimu-
lation that was noted in 20–30 min after injections and lasted
40–45 min before the animals’ behaviour was not different
again from that of intact rats. Symptoms of respiratory insuf-
ficiency or food and drink intake disorders were also not seen.
Statistical analysis
The differences in mean value of the various treatment groups
were analysed by Scheffe’s multiple comparisons in one-way
analysis of variance (anova). The interaction of drug treat-
ment and treatment period was analysed by two-way anova.
Comparison of parametric variables was made by unpaired
sample t-test. All the data were expressed as mean ± SD. A
P-value <0.05 was considered statistically significant.
Results
There was no mortality of animals attributable to the proce-
dure. There were no late deaths during the study period. At
baseline and at the end of the study, there was no difference
in body weight between MI and control rats.
L-17 effects on blood biochemical values in the course of
experimental MI are shown in Table 1.
Table 1 Biochemical values of blood serum in the course of experimental acute MI
Values
Intact rats
(n = 10)
Animals with experimental acute MI
MI, Day 1 MI, Day 5 MI, Day 7
Untreated
(n = 5)
L-17 compound
(n = 5)
Untreated
(n = 5)
L-17 compound
(n = 5)
Untreated
(n = 5)
L-17 compound
(n = 5)
CPK (lmol ⁄
L-min)
146.92 ± 22.6 234.9 ± 60.1* 201.08 ± 28.5* 168.54 ± 21.6* 103 ± 12.1 248.12 ± 41.5* 107.64 ± 19.9
AST (lmol ⁄
L-24 h)
0.193 ± 0.014 0.415 ± 0.033** 0.379 ± 0.022* 0.290 ± 0.05* 0.184 ± 0.011 0.288 ± 0.023* 0.225 ± 0.024
LDH1-2
(lmol ⁄
L-24 h)
165.15 ± 34.6 515.82 ± 60.1* 403.78 ± 38.4** 262.28 ± 22.1* 258.08 ± 31.6* 346.46 ± 52.9* 229.74 ± 60.6*
Reliability of differences between intact animals and animals with an experimental MI: *P < 0.05; **P < 0.01; reliability of differences
between animals that received and did not receive L-17 compound: P < 0.05; P < 0.01. AST, aspartate aminotransferase; CPK, creatine
phosphokinase; MI, myocardial infarction.
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Levels of enzymes
Biochemical analysis in animals with untreated experimental
MI showed that the, levels of all detectable enzymes
exceeded the respective values in intact animals significantly,
whereas in the group treated by L-17 compound, AST and
CPK levels at days 5 and 7 of experiments did not differ sig-
nificantly from the values of intact animals. Besides, these
levels were significantly lower compared with those of the
untreated experimental MI group: for AST at days 1, 5 and
7 and for CPK for days 5 and 7. A similar trend was found
for LDH1-2 values in treated and untreated experimental
MI groups.
In the untreated experimental MI group, there were signif-
icantly increased CPK and LDH1-2 levels at day 7. This sug-
gests possible the recurrence of MI that was probably
induced by active motions of the animals. In the experimen-
tal MI group treated with L-17, there was no statistically
significant increase in enzyme levels.
Course of experimental acute myocardial infarction
On the first postoperative day the infarction area in animals
with untreated experimental MI was characterized as
transmural, as evidenced by the presence of cardiomyocytes
with signs of karyolysis, plasmolysis and plasmorrhexis.
There was moderate diffuse infiltration of the damaged area
with segmented leucocytes without formation of a demarca-
tion zone (Figure 2). Oedema, and fullness of endomysial
vessels with sludge formation was observed in the adjacent
structures. Detectable polymorphonuclear leucocytes in the
area of destruction were indicative of reactive inflammation
with exudative response. Red blood cell sludge formation
and focal haemorrhages were detected in microvessels of the
perifocal area.
Significant changes were seen not only in the necrosis area
but also in adjacent tissues. These changes included partial
atrophy of myocardiocytes, marked dystrophic reaction with
stromal oedema, and loss of cross and axial striation of
myofibrils (Figure 3).
On the first postoperative day in the experimental MI ani-
mal group treated with L-17, the infarction area was large,
focal and showed cardiomyocytes with signs of karyolysis,
plasmolysis and plasmorrhexis without a clear demarcation
zone. Small numbers of lymphocytes were present in the
infiltrate. The necrotic area was minimally infiltrated
(Figure 4).
Figure 2 Myocardial infarction, day 1, without administration
of the preparation. Necrosis area (a) is represented with cardio-
myocytes with signs of karyolysis, plasmolysis and plasmorrhex-
is; moderate diffuse infiltration (b) of injured area with
segmented leukocytes. H&E staining. Magnification · 400.
Figure 3 Myocardial infarction, day 1, without administration
of the preparation. Fullness of endomysial vessels with sludge
formations. H&E staining. Magnification · 400.
Figure 4 Myocardial infarction, day 1, with preparation
administered. Damaged area (a) is represented with cardiomyo-
cytes with signs of karyolysis, plasmolysis and plasmorrhexis;
moderate diffuse infiltration (b) of the injured area is less
marked; infiltrate contains small numbers of lymphocytes. H&E
staining. Magnification · 400.
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On the fifth postoperative day in animals with untreated
experimental MI the necroyic area was characterized as pre-
dominantly transmural. Necrotic cardiomyocytes were sur-
rounded by a demarcation line; and few signs of granulation
tissue formation were observed: fibroblasts and haemocapil-
laries had begun to appear. Adjacent structures demon-
strated infiltration of endomysium.
On the fifth postoperative day in experimental MI animals
treated with L-17 compound, the injured area was replaced
by granulation tissue represented by fibroblasts, fine collagen
fibres and multiple sinusoidal capillaries. Granulation tissue
was infiltrated with lymphocytes and macrophages, but there
were few polymorphonuclear leucocytes.
On seventh postoperative day in all animals with
untreated experimental MI, the necrotic area in the left ven-
tricular wall was characterized as transmural. Histological
signs of the formation stage appeared (i.e. granulation tissue
formation on the edges of the necrosis area with large
amount of fibroblasts, macrophages and sinusoidal haemo-
capillaries replacing the injured area); however, disintegra-
tion of muscular cells and infiltration of myocardium with
lymphocytes and segmented leucocytes persisted. In some
cases, margination with signs of leucopedesis was detected
within vessels.
On seventh postoperative day in experimental MI animals
treated with L-17 compound, the necrotic area was com-
pletely replaced with granulation tissue, in which multiple
sinusoidal-type haemocapillaries, formation of fine collagen
fibres, increased intercellular ground substance, in which
significant number of functionally active fibroblasts and
macrophages were detectable. The Infiltrate was composed
of lymphocytes with small numbers of polymorphonuclear
leucoctes. Signs of interstitial oedema persisted in the adja-
cent myocardial areas; endomysial vessels were dilated and
full.
Discussion
The present study investigated the effects of L-17 compound
of the group of substituted 5R1, 6H2-1,3,4-thiadiazine-2-
amines on inflammatory cellular infiltration and myocardial
remodelling after acute MI in rats.
Laboratory studies of the effects of L-17 compound on
the development and course of experimental MI showed that
L-17 compound administration significantly decreases the
blood AST and CPK levels. Given the data about correlation
between activity of these enzymes and the dimensions of the
necrotic area, it allows one to draw some provisional con-
clusions about effectiveness in treating MI.
Histology findings in animals with experimental MI
deserve special attention. L-17 compound was found not
only to decrease the area of initial infarction but also to
change the pattern of inflammatory reaction in the damaged
myocardium fundamentally.
Basically, reduction in the amount of irreversibly damaged
tissue in itself can be a major factor determining the clinical
presentation of MI and its prognosis (Golikov, 2004); how-
ever, as it turned out, L-17 compound administration leads
to replacement of the exudative destructive inflammation,
which is mainly driven by polymorphonuclear leucocytes,
with cellular productive inflammation characterized by the
dominance by mononuclear cells in the infiltrate. It is prob-
ably the development of the exudative destructive inflamma-
tion that can aggravate ischaemia and reperfusion injury to
the myocardium and contribute to the spread of the area of
necrotic tissue (Tommasi et al. 1999).
Thus, the studies performed here showed that L-17 com-
pound provides an essentially new approach to MI treat-
ment, which means changing the pattern of inflammatory
reaction in such a way as to allow the domination of protec-
tive physiological reactions of a body.
Conclusions
The use of the L-17 compound in experimental MI induces
replacement of exudative destructive inflammation with cel-
lular productive inflammation, which leads to reduction in
the initial necrotic area and decrease in myocardial ischae-
mia and reperfusion injury and accelerates the repair pro-
cess.
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